HALLAHAN DENNIS E has a total of 16 patent applications. Its first patent ever was published in 2002. It filed its patents most often in United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, medical technology and biotechnology are ONCOPEP INC, GOLDENBERG MILTON DAVID and MALLINCKRODT VETERINARY LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 12 | |
#2 | WIPO (World Intellectual Property Organization) | 4 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Medical technology | |
#3 | Biotechnology | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Peptides | |
#3 | Electrotherapy | |
#4 | Therapeutic chemical compounds | |
#5 | Diagnosis and surgery | |
#6 | Analysing materials | |
#7 | Measuring microorganism processes | |
#8 | Measuring electric variables |
# | Name | Total Patents |
---|---|---|
#1 | Hallahan Dennis E | 16 |
#2 | Qu Shimian | 5 |
#3 | Han Zhaozhong | 4 |
#4 | Mernaugh Raymond | 1 |
#5 | Yazlovitskaya Eugenia M | 1 |
#6 | Tan Jiahuai | 1 |
#7 | Willey Christopher D | 1 |
Publication | Filing date | Title |
---|---|---|
US2009136487A1 | Bmx mediated signal transduction in irradiated vascular endothelium | |
US2008262286A1 | Specific inhibition of cPLA2 enhances the efficacy of radiotherapy | |
US2007065361A1 | Ligands to radiation-induced molecules | |
US2009041863A1 | Use of GSK3 inhibitors in combination with radiation therapies | |
WO2006028993A2 | Assessment of cancer susceptibility to molecular targeted therapy by use of recombinant peptides | |
WO03059153A2 | Composition and imaging methods for pharmacokinetic and pharmacodynamic evaluation of therapeutic delivery system |